| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc. | 2.01B | 15.23 | 387.53 | 33.97% | 29.28% | 21.28% | 2.2% | 0.21 |
| ARGXargenx SE | 49.47B | 799.33 | 62.55 | 78.6% | 23.34% | 15.14% | 0.01 | |
| INVAInnoviva, Inc. | 1.48B | 19.74 | 54.83 | 15.54% | 32.78% | 12.61% | 12.77% | 0.65 |
| GLPGGalapagos N.V. | 2.25B | 34.12 | 30.46 | 14.99% | -151.94% | -15.16% | 0.00 | |
| PTGXProtagonist Therapeutics, Inc. | 5.33B | 85.23 | 20.15 | 6.24% | 21.94% | 7.11% | 3.43% | 0.02 |
| ALMSAlumis Inc. Common Stock | 2.86B | 24.34 | -2.34 | -11.08% | -63.71% | 0.12 | ||
| ZBIOZenas BioPharma, Inc. | 1.21B | 22.56 | -6 | -90% | -12.66% | -96.68% | 0.00 | |
| ORKAOruka Therapeutics, Inc. | 1.55B | 32.00 | -6.41 | -22.44% | 0.00 |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Sales/Revenue | 0 | 50M | 5M |
| Revenue Growth % | - | - | -0.9% |
| Cost of Goods Sold | 61.69M | 0 | 139.14M |
| COGS % of Revenue | - | - | 27.83% |
| Gross Profit | -61.69M | 50M | -134.14M |
| Gross Margin % | - | 1% | -26.83% |
| Gross Profit Growth % | - | 1.81% | -3.68% |
| Operating Expenses | 14.51M | 87.15M | 29.75M |
| OpEx % of Revenue | - | 1.74% | 5.95% |
| Selling, General & Admin | 13.51M | 17.11M | 29.75M |
| SG&A % of Revenue | - | 0.34% | 5.95% |
| Research & Development | 62.69M | 60.03M | 139.14M |
| R&D % of Revenue | - | 1.2% | 27.83% |
| Other Operating Expenses | -61.69M | 10M | -139.14M |
| Operating Income | -76.2M | -37.15M | -163.89M |
| Operating Margin % | - | -0.74% | -32.78% |
| Operating Income Growth % | - | 0.51% | -3.41% |
| EBITDA | -76.12M | -37.03M | -163.75M |
| EBITDA Margin % | - | -0.74% | -32.75% |
| EBITDA Growth % | - | 0.51% | -3.42% |
| D&A (Non-Cash Add-back) | 78K | 113K | 137K |
| EBIT | -75.2M | -27.15M | -163.89M |
| Net Interest Income | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 |
| Other Income/Expense | -43.08M | 324K | 7.33M |
| Pretax Income | -119.28M | -36.82M | -156.56M |
| Pretax Margin % | - | -0.74% | -31.31% |
| Income Tax | 0 | 301K | 429K |
| Effective Tax Rate % | 1% | 1.01% | 1% |
| Net Income | -119.28M | -37.12M | -156.99M |
| Net Margin % | - | -0.74% | -31.4% |
| Net Income Growth % | - | 0.69% | -3.23% |
| Net Income (Continuing) | -119.28M | -37.12M | -156.99M |
| Discontinued Operations | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| EPS (Diluted) | -3.11 | -0.97 | -3.76 |
| EPS Growth % | - | 0.69% | -2.88% |
| EPS (Basic) | -3.11 | -0.97 | -3.76 |
| Diluted Shares Outstanding | 38.32M | 38.32M | 41.79M |
| Basic Shares Outstanding | 38.32M | 38.32M | 41.79M |
| Dividend Payout Ratio | - | - | - |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Total Current Assets | 68.44M | 59.8M | 355.92M |
| Cash & Short-Term Investments | 67.21M | 56.86M | 350.77M |
| Cash Only | 67.21M | 56.86M | 319.74M |
| Short-Term Investments | 0 | 0 | 31.02M |
| Accounts Receivable | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - |
| Inventory | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - |
| Other Current Assets | 1.24M | 2.95M | 5.16M |
| Total Non-Current Assets | 6.13M | 8.38M | 14.04M |
| Property, Plant & Equipment | 1.8M | 1.01M | 1.19M |
| Fixed Asset Turnover | - | 49.31x | 4.21x |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 |
| Other Non-Current Assets | 4.33M | 7.36M | 12.86M |
| Total Assets | 74.58M | 68.18M | 369.97M |
| Asset Turnover | - | 0.73x | 0.01x |
| Asset Growth % | - | -0.09% | 4.43% |
| Total Current Liabilities | 25.97M | 23.26M | 57.29M |
| Accounts Payable | 5.82M | 5.4M | 17.14M |
| Days Payables Outstanding | 34.41 | - | 44.95 |
| Short-Term Debt | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 |
| Other Current Liabilities | 4.33M | 5.12M | 8.31M |
| Current Ratio | 2.64x | 2.57x | 6.21x |
| Quick Ratio | 2.64x | 2.57x | 6.21x |
| Cash Conversion Cycle | - | - | - |
| Total Non-Current Liabilities | 240.9M | 270.64M | 218K |
| Long-Term Debt | 0 | 20.3M | 0 |
| Capital Lease Obligations | 812K | 257K | 218K |
| Deferred Tax Liabilities | 0 | 0 | 0 |
| Other Non-Current Liabilities | 240.09M | 250.09M | 0 |
| Total Liabilities | 266.87M | 293.9M | 57.51M |
| Total Debt | 1.53M | 21.11M | 1M |
| Net Debt | -65.68M | -35.74M | -318.74M |
| Debt / Equity | - | - | 0.00x |
| Debt / EBITDA | - | - | - |
| Net Debt / EBITDA | - | - | - |
| Interest Coverage | - | - | - |
| Total Equity | -192.29M | -225.72M | 312.46M |
| Equity Growth % | - | -0.17% | 2.38% |
| Book Value per Share | -5.02 | -5.89 | 7.48 |
| Total Shareholders' Equity | -192.29M | -225.72M | 312.46M |
| Common Stock | 0 | 0 | 4K |
| Retained Earnings | -193.28M | -230.4M | -387.39M |
| Treasury Stock | 0 | 0 | 0 |
| Accumulated OCI | -41K | 37K | 194K |
| Minority Interest | 0 | 0 | 0 |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Cash from Operations | -65.65M | -30.53M | -119.67M |
| Operating CF Margin % | - | -0.61% | -23.93% |
| Operating CF Growth % | - | 0.53% | -2.92% |
| Net Income | -119.28M | -37.12M | -156.99M |
| Depreciation & Amortization | 78K | 113K | 137K |
| Stock-Based Compensation | 737K | 3.5M | 10.82M |
| Deferred Taxes | 0 | 0 | 0 |
| Other Non-Cash Items | 44.85M | 11.03M | 925K |
| Working Capital Changes | 7.97M | -8.04M | 25.43M |
| Change in Receivables | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 |
| Change in Payables | 1.09M | -418K | 11.74M |
| Cash from Investing | -2.2M | -17K | -30.55M |
| Capital Expenditures | -198K | -17K | -131K |
| CapEx % of Revenue | - | 0% | 0.03% |
| Acquisitions | - | - | - |
| Investments | - | - | - |
| Other Investing | -2M | 0 | 0 |
| Cash from Financing | 59.39M | 20.12M | 412.96M |
| Debt Issued (Net) | - | - | - |
| Equity Issued (Net) | - | - | - |
| Dividends Paid | 0 | 0 | 0 |
| Share Repurchases | - | - | - |
| Other Financing | 0 | 0 | -6.06M |
| Net Change in Cash | - | - | - |
| Free Cash Flow | -67.85M | -30.55M | -119.81M |
| FCF Margin % | - | -0.61% | -23.96% |
| FCF Growth % | - | 0.55% | -2.92% |
| FCF per Share | -1.77 | -0.80 | -2.87 |
| FCF Conversion (FCF/Net Income) | 0.55x | 0.82x | 0.76x |
| Interest Paid | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Return on Equity (ROE) | - | - | -361.99% |
| Gross Margin | - | 100% | -2682.78% |
| Net Margin | - | -74.25% | -3139.76% |
| Debt / Equity | - | - | 0.00x |
| FCF Conversion | 0.55x | 0.82x | 0.76x |
| Revenue Growth | - | - | -90% |
Zenas BioPharma, Inc. (ZBIO) reported $15.0M in revenue for fiscal year 2024.
Zenas BioPharma, Inc. (ZBIO) saw revenue decline by 90.0% over the past year.
Zenas BioPharma, Inc. (ZBIO) reported a net loss of $189.9M for fiscal year 2024.
Zenas BioPharma, Inc. (ZBIO) has a return on equity (ROE) of -362.0%. Negative ROE indicates the company is unprofitable.
Zenas BioPharma, Inc. (ZBIO) had negative free cash flow of $158.6M in fiscal year 2024, likely due to heavy capital investments.